Estados Unidos · Revistas de economía · Markets Insider (Business Insider)

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntingtonâs Disease

Publicado por Markets Insider (Business Insider) · Estados Unidos hace 7 h

~ FDA sets PDUFA target action date of May 1, 2027 ~~ If approved, ifezuntirgene inilparvovec will be the worldâs first disease-modifying...

Leer el artículo completo en Markets Insider (Business Insider) Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (markets.businessinsider.com)

También te puede interesar

Martha Stewart Promoted Her QVC Line With a Homelessness Costume. Critics Called It ‘Ridiculously Offensive’

10 highest mountains in the world, from Everest at 8,849 meters to Annapurna I

The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash

Meta’s web crawlers are making life hell for owners of small business websites

Hackers Stole $6.3 Billion From Binance in the Biggest Crypto Heist Ever — Will Users Get Their Money Back?

Did I Miss My Chance to Do a Roth Conversion?